Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorsMariagrazia Pizza, Antonella Bartoloni, Rino Rappuoli
Life of this patent
Estimating the term…
Abstract
Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganism transformed with a hybrid plasmid including the gene/s which codes for at least one of said polypeptides in a suitable medium and recovering the desired polypeptide from the cells or from the culture medium.
Claims5
An immunoprotective modified pertussis toxin consisting of S1, S2, S3, S4 and S5 pertussis toxin subunits with the same arrangement and configuration presented by the natural pertussis toxin, wherein said modified pertussis toxin has no or reduced toxicity, wherein said modified pertussis toxin is modified by direct mutagenesis of the pertussis toxin S1 subunit gene, wherein the direct mutagenesis removes or replaces a single amino acid, wherein said single amino acid is GLU129 in the S1 subunit.
A modified pertussis toxin consisting of S1, S2, S3, S4, and S5 pertussis toxin subunits with the same arrangement and configuration presented by the natural pertussis toxin, wherein the modified pertussis toxin is modified by direct mutagenesis of the pertussis toxin gene S1 subunit to have amino acid GLU129 replaced by Gly, wherein the modified pertussis toxin has no or reduced toxicity, wherein said S1 subunit of said modified pertussis toxin is reactive with antipertussis toxin protective monoclonal antibodies.
A modified pertussis toxin consisting of S1, S2, S3, S4, and S5 pertussis toxin subunits with the same arrangement and configuration presented by the natural pertussis toxin, wherein the modified pertussis toxin is modified by direct mutagenesis of the pertussis toxin gene S1 subunit to have amino acids Phe50 and Thr53 replaced by Glu and Ile, respectively, wherein said S1 subunit of said modified pertussis toxin is reactive with antipertussis toxin protective monoclonal antibodies.
A modified pertussis toxin consisting of S1, S2, S3, S4, and S5 pertussis toxin subunits with the same arrangement and configuration presented by the natural pertussis toxin, wherein the modified pertussis toxin is modified by direct mutagenesis of the pertussis toxin gene S1 subunit to have amino acids Tyr8 and Arg9 replaced by Asp and Gly, respectively, wherein said S1 subunit of said modified pertussis toxin is reactive with antipertussis toxin protective monoclonal antibodies.
Dependencies are inferred from the claim text.